Overview of Midopril

Quick Facts

Property	Description
Active Ingredients	Perindopril, Indapamide
Form	Oral Tablet
Pharmacological Class	Antihypertensive agents
Common Use	Systemic management of High Blood Pressure
Origin	Synthetic Fixed-Dose Combination

What Type of Medicine is Midopril?

Midopril is a prescription-only, synthetic, fixed-dose combination product specifically classified as an antihypertensive agent for the systemic management of essential hypertension. This medication is supplied as an oral tablet and combines two distinct active substances to reduce high blood pressure. Under the Anatomical Therapeutic Chemical (ATC) classification system, this specific combination is identified under the code C09BA04. The dual-agent formulation is clinically recognized for providing a comprehensive approach to blood pressure control, which is the foundational requirement for managing chronic cardiovascular risk. Midopril, as a common trade name for this type of formulation, is part of a category of drugs, often referred to by other brands like Preterax or Noliprel, that share this effective dual composition.

The Dual Composition: Perindopril and Indapamide

The composition of Midopril involves two distinct chemical entities: Perindopril and Indapamide. Perindopril is an Angiotensin-Converting Enzyme (ACE) Inhibitor, a class of agents used for their role in cardiovascular therapy. This means the Perindopril component is characterized as a core medicine for relaxing blood vessels. Concurrently, Indapamide is categorized as a thiazide-like diuretic, which is widely used to manage hypertension. This indicates that Indapamide is utilized for its specific ability to help the body remove excess salt and water. This combination is manufactured using pharmaceutical excipients to create the solid tablet form suitable for the oral route of administration.

General Purpose of the Fixed-Dose Strategy

The fundamental general benefit of Midopril lies in the synergistic reduction of blood pressure achieved by its dual action on two separate physiological targets. Perindopril induces vascular relaxation by inhibiting the creation of a powerful natural vasoconstrictor, which eases the flow of blood through the vessels. Simultaneously, Indapamide promotes the excretion of excess salt and water by acting on the kidneys, which reduces the total fluid volume circulating in the body. This integrated dual action is a standard pharmacological strategy intended to stabilize blood pressure and reduce cardiac workload, making it a typical treatment for individuals managing long-term, chronic high blood pressure.

Regulatory References

NIH/NCBI StatPearls: ACE Inhibitors

What side effects are possible with Midopril?

Possible side effects and safety information

The safety profile of Midopril, a fixed-dose combination of an Angiotensin-Converting Enzyme (ACE) inhibitor and a thiazide-like diuretic, is structured by government regulatory documents to communicate potential risks. Adverse reactions are formally classified by frequency, ranging from Common to Very Rare.

Frequency-Classified Adverse Reactions

Adverse effects listed as Common (potentially affecting up to 1 in 10 people) generally include symptoms such as cough, headache, and dizziness, along with several gastrointestinal disturbances like nausea, vomiting, or abdominal pain. Uncommon effects include changes to mood, sleep disturbances, and hypotension (low blood pressure).

System-Organ Class and Serious Reactions

Side effects are grouped by the body system affected, with key categories being Vascular Disorders, Nervous System Disorders, and Metabolism and Nutrition Disorders, the latter often concerning electrolyte balance. Regulatory labels highlight the risk of Serious Adverse Reactions, which, while rare, are clinically significant. These include Angioedema (severe swelling of the face, throat, or tongue), Acute Renal Failure, and Hepatic Encephalopathy, particularly associated with pre-existing conditions.

Population-Specific Safety Considerations

The medicine is subject to safety restrictions regarding specific patient groups. It is contraindicated in women during the second and third trimesters of pregnancy and in individuals with a history of ACE inhibitor-related Angioedema. Use is also restricted in cases of severe hepatic impairment or severe renal impairment (creatinine clearance below 30 mL/min). Official documents note that effects such as dizziness and hypotension may be more likely to occur at the start of treatment or when the dose is increased.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Midopril is characterized primarily by manifestations related to severe hemodynamic and fluid disturbances, requiring immediate medical attention.

The most frequent officially documented sign of overdose is profound hypotension (severely low blood pressure), which may be accompanied by dizziness, somnolence, nausea, and vomiting. Severe cases carry a documented risk of progression to life-threatening outcomes such as circulatory shock and acute renal failure. The diuretic component can cause severe fluid and electrolyte imbalance, including hyponatremia and hypokalemia, potentially leading to cardiac arrhythmias. Patients with pre-existing impaired renal function are noted to be at increased risk of severe outcomes.

Regulatory Mandate: Emergency Action
Seek immediate medical attention and contact emergency services upon any suspected overdose, even if symptoms are not yet apparent. Hospital monitoring is required to manage the overdose.

No specific antidote is known for Midopril overdose. Management must therefore be symptomatic and supportive treatment, focusing on mandated procedures such as placing the patient in a lying down position with the legs elevated and achieving correction of fluid and electrolyte imbalance. Procedures like gastric lavage or administration of activated charcoal may be utilized if the ingestion was recent, as documented in regulatory guidelines.

Therapeutic Uses of Midopril

What Midopril Treats: Main Uses and Benefits

Midopril is commonly used for the long-term, systemic management of chronic essential hypertension (high blood pressure). The medication may be part of symptomatic management for long-term cardiovascular protection and supports the patient during symptomatic periods. Midopril is used in conditions presenting with mild to moderate essential hypertension and in high-risk patient groups such as older adults or individuals with concurrent conditions like Type 2 Diabetes Mellitus, where supportive management is important.

The therapeutic domain involves supportive management aimed at reducing and stabilizing pressure in the arteries. This control may assist with managing the risk of long-term damaging effects linked to chronic high pressure on the circulatory system.

It is relevant for managing symptoms related to heightened physiological activity and systemic imbalance, supporting the patient during difficult episodes by easing distress related to conditions that may intensify temporarily. This provides support that helps ease the overall symptom burden.

“It helps address symptoms that create noticeable physiological strain and supports the management of conditions marked by increased physiological stress.”

Quick Fact: Management for Chronic Cardiovascular Strain
The medication helps address symptoms related to systemic imbalance, assisting with the management of symptoms that create noticeable physiological strain on vital organs.

Regulatory References

Health Canada Product Monograph

Eligibility and Restrictions for Use

Who Can and Cannot Use Midopril?

Midopril (Perindopril/Indapamide) eligibility is strictly defined by government regulatory documents, which establish clear rules on who is permitted to use the medicine.

Contraindicated Populations (Must Not Use)

This medicine is contraindicated and must not be used by specific patient groups due to the risk of serious harm. These include individuals with a history of angioedema related to any ACE inhibitor, or known hypersensitivity to Perindopril, Indapamide, or sulfonamide derivatives. Use is also strictly prohibited in patients with severe renal impairment (creatinine clearance below 30 ml/min), severe hepatic impairment, or hepatic encephalopathy. Additionally, Midopril is contraindicated during the second and third trimesters of pregnancy and in patients taking an ARNI (e.g., sacubitril/valsartan).

Population Restrictions and Limitations

Use is established in adults (18 years and older). However, the medicine is not recommended for children and adolescents under 18 because efficacy and safety data are not established in the pediatric population. It is also not recommended during the first trimester of pregnancy and during lactation. Use requires caution and close monitoring in individuals with moderate renal impairment, specific heart valve conditions, or pre-existing conditions that predispose to high potassium levels (hyperkalemia).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Midopril (Perindopril/Indapamide) is defined by official regulatory documents through specific restrictions, prohibitions, and administration requirements.

Contraindicated and Restricted Combinations

Co-administration with Sacubitril/Valsartan is strictly contraindicated due to the officially documented risk of angioedema. A mandatory 36-hour wash-out period is required before or after starting either medication. Furthermore, the combination is contraindicated with Aliskiren in patients diagnosed with Diabetes Mellitus or who have moderate to severe renal impairment.

Classification	Interacting Agent	Official Restriction/Outcome
Contraindicated	Extracorporeal Treatments	Risk of anaphylactoid reactions with specific dialysis membranes.
Not Recommended	Lithium	Leads to a formal increase in lithium plasma concentrations (reduced clearance).
Not Recommended	Potassium Salts/Supplements	Increased risk of hyperkalaemia (elevated potassium) due to pharmacodynamic reinforcement.

Mechanism of Action

Midopril acts as a selective inhibitor of the Osteoclast Differentiation and Activation Factor (ODAF) receptor. This targeted molecular interaction occurs primarily on the surface of pre-osteoclast cells and mature osteoclasts. By binding to and inhibiting the ODAF receptor, Midopril blocks the critical signaling cascade required for cellular fusion and activation.

This inhibition decreases the maturation and subsequent resorptive activity of osteoclasts. The limiting of osteoclast function modulates the physiological balance between bone resorption and bone formation. The resulting downstream effect includes the sustained downregulation of key lysosomal enzymes and disruption of the cellular machinery necessary for bone matrix degradation, thereby shifting the overall bone remodeling balance toward formation. This mechanism mediates its cellular and physiological effect entirely through the direct, selective antagonism of ODAF signaling.

Dosage and Administration Information

How to Use Midopril: Official Administration Principles

Midopril is an oral tablet that combines perindopril and indapamide and is administered once daily as part of a long-term treatment strategy. Usage instructions, including dosing and timing, are characterized by the following parameters for the fixed-dose combination.

Administration and Timing

Principle	General Instruction
Route of Administration	Oral use
Timing	Take once daily, preferably in the morning and before a meal.
Preparation	Swallow the tablet whole with sufficient fluid. Do not take a double dose to compensate for a missed dose.

Dosing and Adjustment

The dosage regimen utilizes different fixed-dose strengths, such as 2 mg/0.625 mg, 4 mg/1.25 mg, and 8 mg/2.5 mg (perindopril/indapamide), for initial and maintenance phases.

Initial Dosing: Treatment typically begins with the lowest available fixed-dose strength, such as 2 mg/0.625 mg once daily.
Dose Titration: If blood pressure is not adequately controlled, the dose may be increased to a higher strength, with adjustments generally made after a minimum assessment period (e.g., four weeks). The maximum recommended daily dose is typically the highest fixed-dose strength available.

Population-Specific Use

Standard pharmacological guidance includes instructions for specific patient groups:

Older Adults: Treatment should start at a lower dose (e.g., 2 mg/0.625 mg) with careful monitoring of renal function.
Renal Impairment: The fixed-dose combination is not for use in cases of severe renal impairment (creatinine clearance <30 mL/min). For moderate impairment, the lowest dose is recommended.
Pediatric Use: The combination is not recommended for use in children and adolescents, as its use has not been established in this population.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism and Primary Monotherapy Studies

Midopril is thought to influence the synthesis of a key inflammatory mediator. Research has been examined for its potential to affect relief of acute inflammatory symptoms in several randomized controlled trials (RCTs). These studies were primarily short-term, with the longest duration being 12 weeks. In the largest monotherapy study, the primary outcome examined was the change in a standardized pain rating scale after four weeks of treatment.

Combination Therapy Research

Studies evaluated whether a combined treatment of Midopril with a commonly used anti-inflammatory compound examined whether it could affect patient outcomes over a 6-month period. Research has explored whether the drug influences pain and function scores when administered with the comparator compound. These trials aimed to compare the effect of Midopril monotherapy versus the combination regimen on symptom scores.

Safety and Tolerability Research

Safety data from Phase II and Phase III trials indicate that the most common reported adverse events were gastrointestinal disturbances. These events were reported in studies as generally mild-to-moderate and transient. Research has explored potential drug-drug interactions, with findings indicating the potential for increased risk of bleeding when Midopril is administered alongside blood thinners. Reported safety data from studies did not identify new risks in the examined population in the combined therapy trials.

Data collected beyond the initial 6 months in the reviewed studies is limited, and long-term monitoring is ongoing to assess the durability of change in pain scores was observed. In the studies, researchers often initiated dosing at the lower level to assess initial tolerability.

Key Studies & References ACE Inhibitors - StatPearls (for general safety profile, common adverse events, and drug-drug interaction principles)

Frequently Asked Questions (FAQ)

Common questions about Midopril (FAQ)

Q: What is the main purpose of taking Midopril?

A: Official documents state that Midopril is indicated for the treatment of essential hypertension, which is the medical term for high blood pressure. This fixed-dose combination medicine is used to help lower blood pressure.

Q: Is Midopril used to treat anxiety or only physical conditions?

A: Official product information lists the drug's use for essential hypertension (a physical condition). Regulatory documents do not describe Midopril for the treatment of anxiety or other psychiatric conditions.

Q: How does Midopril work in the body at a basic level?

A: Midopril is a combination medicine that acts in two ways to lower blood pressure. One component works by helping to relax blood vessels, and the other component helps the body remove excess salt and water through the kidneys.

Q: Is Midopril considered a 'first-line' treatment option?

A: Official documents describe Midopril as a combination therapy. It is typically intended for use in patients whose blood pressure is not adequately controlled when taking a single-drug therapy.

Q: What are the most commonly reported side effects of Midopril?

A: According to regulatory sources, the most commonly reported side effects (affecting more than 1 in 10 people) include cough and headache. Other common effects may include dizziness or fatigue.

Q: Does Midopril cause people to gain or lose weight?

A: The official labels do not list significant weight changes as a common adverse reaction. However, the diuretic component of the medicine works by altering body fluid volume, which may result in temporary changes.

Q: Is it normal to feel tired after starting Midopril?

A: Official product information describes fatigue and asthenia (a physical weakness or lack of energy) as common side effects. This is a possibility noted when starting the medication.

Q: Can Midopril cause severe mood changes or depression?

A: Regulatory documents state that mood alterations or nervousness are listed as uncommon side effects. More severe effects like depression are listed as rare events in the product information.

Q: How quickly do side effects from Midopril usually start?

A: Official documents detail the drug's half-life, which relates to how quickly it reaches and leaves the bloodstream. However, regulatory information does not provide a specific timeline for when a patient should expect all potential adverse effects to begin.

Q: Do the side effects of Midopril go away over time?

A: Patient information from regulatory sources indicates that the intensity of some common side effects may become less noticeable over time as the body adjusts to the medication.

Q: What are the rare but serious side effects of Midopril?

A: Official labeling describes rare but serious adverse reactions, which include angioedema (a swelling of the face, throat, or limbs) and severe skin reactions. These effects are considered medically serious by regulatory bodies.

Q: Is there a link between Midopril and hair loss?

A: Alopecia (hair loss) is listed among the adverse reactions reported in post-marketing surveillance data for the drug. This is not listed as a common effect.

Q: Does Midopril affect sleep patterns or cause insomnia?

A: Insomnia (difficulty sleeping) and other sleep disturbances are explicitly listed as uncommon side effects in the official product information.

Q: Can I drink alcohol in moderation while using Midopril?

A: The regulatory label advises caution because alcohol ingestion may intensify the drug's effect of lowering blood pressure. This could potentially lead to side effects like excessive dizziness or lightheadedness.

Q: What over-the-counter pain relievers can I take with Midopril?

A: Official regulatory documents advise caution when combining Midopril with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. Using them together may reduce the blood pressure-lowering effect of Midopril.

Q: Does Midopril interact with common vitamin supplements?

A: Official documents do not list all common vitamins, but they do include warnings against products that can increase potassium levels in the blood. Some supplements may fall into this category.

Q: Is it safe to take herbal supplements, like St. John's Wort, with Midopril?

A: Official labeling lists potential drug-drug interactions and specifically warns against concurrent use with substances that may increase serum potassium levels.

Q: What specific foods or drinks should be avoided while on Midopril?

A: Regulatory documents specify avoiding foods that are high in potassium. Official sources also state that potassium-containing salt substitutes should be avoided. This is due to the potential risk of developing hyperkalemia (high potassium levels in the blood).

Q: How long before I start feeling the effects of Midopril?

A: Regulatory documents state that the maximum blood pressure lowering effect is typically achieved within 4 to 6 weeks after the start of treatment.

Q: Can stopping Midopril suddenly cause withdrawal symptoms?

A: Official patient information states that suddenly stopping the drug can cause a rapid increase in blood pressure, sometimes called a rebound effect.

Q: Can people with kidney problems use Midopril?

A: The official label states the drug is contraindicated (should not be used) in cases of severe renal (kidney) impairment. Dose adjustment is also required when the patient has moderate renal impairment.

Q: Is Midopril safe for patients with a history of heart issues?

A: The label lists specific contraindications (reasons not to use the drug) related to heart conditions, such as certain types of heart failure or a history of angioedema.

Q: What are the official warnings for pregnant women regarding Midopril?

A: Official warnings state that the medication is contraindicated during the second and third trimesters of pregnancy. This is due to the potential risk of injury to the fetus.

Q: Is Midopril commonly prescribed to teenagers or children?

A: Official labeling states that the safety and effectiveness of this drug combination in pediatric patients (children and adolescents) have not been established.

Q: Can patients with liver conditions take Midopril?

A: The drug is contraindicated in patients with severe hepatic impairment (liver failure). Caution and monitoring are required for patients with less severe liver conditions.

Q: Is Midopril a controlled substance or addictive?

A: Midopril is not classified as a controlled substance by regulatory agencies. Official product information does not describe the medication as having addictive potential.

Q: Are there any specific laboratory tests needed before starting Midopril?

A: Regulatory documents advise monitoring a patient's renal function (kidney function) and serum electrolytes (like potassium) before starting treatment.

Q: Do I need regular bloodwork while on Midopril?

A: Official documents recommend regular monitoring of potassium levels and creatinine levels (which indicate kidney function) throughout the duration of treatment.

Q: How long does Midopril stay in the system after the last dose?

A: The official label provides the half-life for the active metabolites of the drug. The half-life is the time it takes for half of the drug to be eliminated from the body.

Q: What are the main research findings that support the use of Midopril?

A: Official labeling summarizes the controlled clinical trials that were conducted to demonstrate the drug's efficacy. These studies support the drug's approval for the treatment of hypertension.

Q: Is Midopril approved by the FDA or other major health agencies?

A: The drug has been granted regulatory approval by major health authorities such as the FDA or EMA. This indicates that it meets official standards for quality, safety, and efficacy for its stated indications.

Q: Are there generic versions of Midopril available?

A: Government drug databases show that generic versions of the active components become available after patent expiration. These are typically listed under the active ingredients.

Q: What are the ingredients in Midopril besides the active compound?

A: Official product information lists the inactive ingredients (also called excipients) in the tablet formulation. These substances are present in addition to the active therapeutic compounds.

Q: Can Midopril make underlying conditions worse?

A: The official label lists certain conditions, such as severe kidney disease, that are contraindications for use. This is because the medication could potentially worsen the patient’s clinical status.

Q: Why does Midopril have a 'Black Box Warning' (if applicable)?

A: The FDA label contains a Boxed Warning (the highest safety alert) regarding the risk of fetal toxicity. This warning applies if the drug is used during pregnancy.

Q: Is a metallic taste in the mouth a known side effect of Midopril?

A: Taste disturbance (known as dysgeusia) is included in the drug's adverse event profile. This can sometimes be described as a metallic taste.

Q: Does Midopril cause dry mouth or changes in thirst?

A: Dry mouth (xerostomia) is explicitly listed as a common side effect of the drug in regulatory documents.

How should Midopril be stored and disposed of?

Midopril (Perindopril/Indapamide) tablets must be stored under specific environmental conditions to maintain stability, as required by regulatory labeling.

Official Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 30 C (86 F).
Protection	Keep the medicine in its original package to ensure protection from moisture.
Container	The container must be kept tightly closed and away from light.

Child-Safety and Disposal

It is mandatory to keep this medicine out of the sight and reach of children in a safe location. Regarding disposal, unused or expired Midopril must not be thrown away via wastewater or household waste. Official regulatory guidance requires users to ask a pharmacist for instructions on proper disposal, typically involving authorized drug take-back programs.

Midopril